TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04234360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 days of systemic corticotherapy (prednisone)
Description: Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 days of systemic corticotherapy (prednisone)
Description: Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 days of placebo
Description: Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 days of placebo
Description: Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Study: NCT06021288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effluent dose of CRRT
Description: The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
Study: NCT05772156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching saline placebo
Study: NCT04020263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 MG/ML Injectable Solution
Description: Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Study: NCT05989477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-home Breast Oncology care Delivered with E-health solutions - ABODE
Description: The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
Study: NCT06303752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRC injection
Description: Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRC001 injection
Description: Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
Study: NCT04286555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower sodium
Description: 1500 mg/day sodium (at the 2000 kilocalorie level)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower sodium
Description: 1500 mg/day sodium (at the 2000 kilocalorie level)
Study: NCT06021288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effluent dose of CRRT
Description: The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
Study: NCT06508723

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implant placement
Description: The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implant placement
Description: The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
Study: NCT05397106

Intervention type: DEVICE
Intervention: CODMAN CERTAS Plus Programmable Valve
Description: Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
Study: NCT06238466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1705
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
Study: NCT06470204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine+Dexamethasone
Description: Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
Study: NCT06494553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stabilization exercises
Description: Neck stabilization exercises included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Description: The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment program
Description: US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment program
Description: US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
Study: NCT05788432

Intervention type: DEVICE
Intervention: Sequent Please Neo
Description: Patients in whom treatment with (Sequent Please Neo) has been attempted
Study: NCT06294236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC291
Description: SC291 is an allogeneic CAR T cell therapy
Study: NCT06494553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared therapy
Description: Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
Study: NCT06294236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC291
Description: SC291 is an allogeneic CAR T cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC291
Description: SC291 is an allogeneic CAR T cell therapy
Study: NCT06494553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared therapy
Description: Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
Study: NCT05156073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: 1. Patient care partner cohort:~   a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~2. Primary care physician cohort:~   1. education on deprescribing through a 15-45-minute presentation~  2. one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations.
Study: NCT05120661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food product
Description: a food product containing 50 gram carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food product
Description: a food product containing 50 gram carbohydrates
Study: NCT05951257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized multimodal intervention involving hypnosis and/or music
Description: The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself.
Study: NCT05948956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Beverage
Description: Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-ketone Powder ™ and electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Beverage
Description: Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-ketone Powder ™ and electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Beverage
Description: Participants will consume an electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Beverage
Description: Participants will consume an electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cycling Intervention
Description: Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Intervention
Description: Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cycling Intervention
Description: Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Intervention
Description: Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down.
Study: NCT06424834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once orally daily.
Study: NCT06150183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT314
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT314
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT06088043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: Specified drug on specified days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified drug on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Specified drug on specified days.
Study: NCT06459583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Platform
Description: The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
Study: NCT06201884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early rehabilitation through Adapted Physical Activity
Description: From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
Study: NCT06347133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plozasiran Injection
Description: ARO-APOC3 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl)
Study: NCT06333067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study: NCT05808309

Intervention type: OTHER
Intervention: Salivary sampling
Description: Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)

Intervention type: OTHER
Intervention: Salivary sampling
Description: Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)

Intervention type: OTHER
Intervention: Salivary sampling
Description: Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)

Intervention type: OTHER
Intervention: Salivary sampling
Description: Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
Study: NCT05916495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid care arm
Description: Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care arm
Description: Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
Study: NCT05741840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBT-A
Description: PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
Study: NCT06459583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videoconference Telehealth Platform
Description: Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
Study: NCT03261375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Artery Radiofrequency Ablation System (Generator and Catheter )
Description: A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antihypertensive Agents
Description: Calcium channel blocker, Diuretic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive Agents
Description: Calcium channel blocker, Diuretic

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Catheterization without renal denervation
Study: NCT05274165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric Hearing Aid- Experimental Design
Description: Extended wear hearing aid with a fitting modification that is currently not available

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric Hearing Aid- Commercially Available
Description: Extended wear hearing aid that is currently available

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric Hearing Aid- Commercially Available
Description: Extended wear hearing aid that is currently available
Study: NCT06266286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (active)
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
Study: NCT05355311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
Study: NCT06215339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet therapy training
Description: diet education